Litcius/Paper detail

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of <i>NTRK1</i>

Matthew L. Hemming, Michael J. Nathenson, Jia‐Ren Lin, Shaolin Mei, Ziming Du, Karan Malik, Adrián Mariño‐Enríquez, Jyothi P. Jagannathan, Peter K. Sorger, Monica M. Bertagnolli, Ewa Sicińska, George D. Demetri, Sandro Santagata

2020JCO Precision Oncology36 citationsDOIOpen Access PDF

Abstract

Patents, Royalties, Other Intellectual Property: US9696313B2 (HSF1 as a marker in tumor prognosis and treatment), US20150241436A1 (Hsf1 and hsf1 cancer signature set genes and uses

Topics & Concepts

Cancer researchSarcomaCell biologyBiologyMedicinePathologyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes
Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of <i>NTRK1</i> | Litcius